公开(公告)号：US11591406B2

公开(公告)日：2023-02-28

申请号：US16693904

申请日：2019-11-25

Applicant: MORPHOSYS AG

Inventor： Stéphane LeClair ,  Jan Endell ,  Stefan Härtle

IPC: A61K39/00 ,  C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K31/573

Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.

公开(公告)号：US11618789B2

公开(公告)日：2023-04-04

申请号：US16080870

申请日：2017-03-03

Applicant: MORPHOSYS AG

Inventor： Stefan Härtle

IPC: C07K16/42 ,  C07K16/18 ,  C07K16/30 ,  G01N33/574 ,  A61P35/00 ,  C07K14/76 ,  G01N33/49 ,  G01N33/561

Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.

公开(公告)号：US20240392034A1

公开(公告)日：2024-11-28

申请号：US18802877

申请日：2024-08-13

Applicant: MORPHOSYS AG

Inventor： Stefan Härtle

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/76 ,  C07K16/42 ,  G01N33/49 ,  G01N33/561 ,  G01N33/574

Abstract: Applicant discloses an anti-idiotypic antibody to MOR202. which when fused to human albumin. shifted the antibody in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.

公开(公告)号：US20240228654A9

公开(公告)日：2024-07-11

申请号：US18548477

申请日：2022-03-01

Applicant: MORPHOSYS AG

Inventor： Stefan Steidl ,  Stefan Härtle ,  Rainer Boxhammer

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565

Abstract: The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.

公开(公告)号：US10533057B2

公开(公告)日：2020-01-14

申请号：US15569495

申请日：2016-05-13

Applicant: MORPHOSYS AG

Inventor： Stéphane LeClair ,  Jan Endell ,  Stefan Härtle

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K31/573

Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.

公开(公告)号：US20200079871A1

公开(公告)日：2020-03-12

申请号：US16693904

申请日：2019-11-25

Applicant: MORPHOSYS AG

Inventor： Stéphane LeClair ,  Jan Endell ,  Stefan Härtle

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K31/573

Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.

公开(公告)号：US20190077875A1

公开(公告)日：2019-03-14

申请号：US16080870

申请日：2017-03-03

Applicant: MORPHOSYS AG

Inventor： Stefan Härtle

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/76 ,  G01N33/49 ,  G01N33/561

Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.

公开(公告)号：US20190048091A1

公开(公告)日：2019-02-14

申请号：US15569495

申请日：2016-05-13

Applicant: MORPHOSYS AG

Inventor： Stéphane LeClair ,  Jan Endell ,  Stefan Härtle

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K31/573

CPC classification number: C07K16/2896 ,  A61K9/0021 ,  A61K31/573 ,  A61K2039/505 ,  A61K2300/00 ,  A61P35/00 ,  C07K2317/21

Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.

公开(公告)号：US20240132618A1

公开(公告)日：2024-04-25

申请号：US18548477

申请日：2022-03-01

Applicant: MORPHOSYS AG

Inventor： Stefan Steidl ,  Stefan Härtle ,  Rainer Boxhammer

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565

Abstract: The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.

公开(公告)号：US20240109977A1

公开(公告)日：2024-04-04

申请号：US18261376

申请日：2022-01-14

Applicant: MORPHOSYS AG

Inventor： Stefan Steidl ,  Stefan Härtle ,  Rainer Boxhammer

IPC: C07K16/28 ,  A61P13/12 ,  A61P37/06

CPC classification number: C07K16/2896 ,  A61P13/12 ,  A61P37/06 ,  A61K2039/505

Abstract: The present invention relates to the use of an anti-CD38 antibody or antibody fragment in the prophylaxis and/or treatment of diseases directly caused by immune complex deposits. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of IgA nephropathy (IgAN).